FEB 2 4 2005

TAXE POP AND AND SECOND
FAX TRANSMISSION
DATE: February 24, 2005
PTO IDENTIFIER: Application Number 09/996357-Conf. #1918
Patent Number
Inventor: Malcolm L. GEFTER et al.
MESSAGE TO: US Patent and Trademark Office
FAX NUMBER: (703) 872-9306
FROM: LAHIVE & COCKFIELD, LLP
Maria Laccotripe Zacharakis, Ph.D., J.D.
PHONE: (617) 227-7400
Attorney Dkt. #: PPI-105
PAGES (Including Cover Sheet): 13
CONTENTS: Amendment Transmittal (1 page)
Amendment Response to Final Action (11 pages)
If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 227-7400 and send the original transmission to us by
return mail at the address below.
This transmission is intended for the sole use of the individual and entity to
and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone
other than the intended addressee or its designated agent is strictly prohibited.
LAHIVE & COCKFIELD, LLP
28 State Street, Boston, Massachusento, 00400
Telephone: (617) 227-7400 Facsimile: (617) 742-4214
·

AMENDMENT TRANSMITTAL LETTER Docket No. PPI-105							
Application No. 09/996357-Conf. #1918 N		Filing November	Date 27, 2001	Examiner C. J. Nichols		Art Unit 1647	
Applicant(s). Malcolm L. GEFTER et al.							
Invention: THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING ANAMYLOIDOGENIC DISEASE							
Transmitted here	with is an ame	nament in the	above-identif	OR PATENTS lied application.			
The fee has been calculated and is transmitted as shown below. CLAIMS AS AMENDED							
	Claims Remaining After	Highest Number Previously	Number Extra Claims	DED			
Total Claims	Amendment 11	- 183 =	Present	Rate X			
Independent Claims	2	- 4 =	Ť	x			
Multiple Dependent Claims (check if applicable)							
Other fee (please specify):							
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT: 0.00							
Large Entity X Small Entity No additional fee is required for this amendment. Please charge Deposit Account No							
A check in the amount of \$ to cover the filing fee is enclosed. Payment by credit card. Form PTO-2038 is attached. X The Director is hereby authorized to charge and credit Deposit Account No							
Credit any overpayment.							
Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17. Maria Laccotripe Zacharakis, Ph. D., J.D. Attorney Reg. No.: 56,266							
LAHIVE & COCK 28 State Street Boston, Massach (617) 227-7400	(FIELD, LLP						
nereby certify that this correspondence is being facsimile transmitted to the Patent and Trademan. Office, facsimile no. (703) 872- 9306 at MF AF, Commissioner for Patents. P O. Box 450 Alexandria, VA 22313-1450, on the date shown below. Dated. February 24, 2005 Signature:							

24-Feb-05 03:26pm From-LAHIVE & COCKFIELD. LLP

6177424214

T-599 P.03/13 F-722

I hereby certify that this correspondence is being facisimile transmitted to the Patent and Trademark Office, facsimile no (703) 872-9306 at MS AF, Commissioner for Patents, P.O. Box 1450, Alexangma, VA 22313-1450, on the

Dated February 24, 2005 Signature

(Mana Laccotripa Zacharakis)

Docket No.: PPI-105

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Patent Application of: Malcolm L. Gefter et al.

CENTRAL FAX CENTER

FEB 2 4 2005

Application No.: 09/996357

Confirmation No.: 1918

Filed: November 27, 2001

Art Unit: 1647

For: THERAPEUTIC AGENTS AND METHODS

Examiner:

OF USE THEREOF FOR TREATING AN AMYLOIDOGENIC DISEASE

NICHOLS, CHRISTOPHER J

AMENDMENT RESPONSE TO FINAL OFFICE ACTION

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Final Office Action mailed November 24, 2004, please amend the application as follows:

Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.